Bml Capital Management Q2 Portfolio Changes: Focus on Healthcare, Consumer Gains
Bml Capital Management's portfolio saw significant shifts this quarter with notable additions and reductions across key sectors.
As of June 30th, Bml Capital Management's total portfolio value stood at $161.0 million.
Major Portfolio Shifts in Q2 2026
This quarter, Bml Capital Management's holdings underwent several significant changes:
- Sell-offs: The largest reduction was observed in ACLARIS THERAPEUTICS INC, which saw a 15.96% decrease in its portfolio weight, likely due to share reductions.
- Slight Reductions: Other notable exits included ORAMED PHARMACEUTICALS INC, which experienced a substantial 72.65% reduction in its portfolio weight, and ATEA PHARMACEUTICALS INC with a minor decrease.
- Purchasing Activity: The investor significantly increased their stake in KRAFT HEINZ CO, boosting its portfolio weight by 272% through share purchases. Other additions included a smaller increase in CARMAX INC.
- New Position: OUTSET MED INC was added to the portfolio, increasing its allocation from scratch to approximately 6.76% of the total value.
Healthcare Sector Dynamics
The dominant Healthcare sector within Bml Capital Management's portfolio saw mixed activity:
- ACLARIS THERAPEUTICS INC (ACRS), a major holding, experienced the most significant weight reduction this quarter.
- PMV PHARMACEUTICALS INC (PMVP) saw a very slight increase in shares and its portfolio allocation.
- ORAMED PHARMACEUTICALS INC's position was drastically cut, highlighting a major divestment within this sub-sector.
- ATEA PHARMACEUTICALS INC (AVIR) maintained its significant allocation but saw only minimal share reduction.
The overall Healthcare sector allocation for Bml Capital Management increased slightly to 72.1% of the total portfolio value, suggesting a continued focus on biopharmaceutical and healthcare companies despite specific reductions like ORAMED.
Consumer Goods and Services Adjustments
In the Consumer space:
- KRAFT HEINZ CO (KHC), classified under Consumer Defensive, showed a massive increase in both shares and portfolio weight.
- CARMAX INC added a small number of shares, increasing its allocation slightly by 1.29 percentage points.
- New Addition: OUTSET MED INC (690145206), categorized under Unknown sector but linked to the biotech field, was incorporated into Bml Capital Management's portfolio, contributing about $10.8 million in value and 6.76% allocation.
Meanwhile, holdings like TARGET CORP (TGT) remained unchanged from the previous quarter's position.
Overall Portfolio Allocation and Stability
Bml Capital Management holds 12 stocks in its portfolio. The top five holdings account for approximately 72.34% of the total value, indicating a concentrated investment strategy. Healthcare remains the largest sector allocation at nearly $116 million (72.1%), followed by Consumer Cyclical ($18.15M or 11.27%) and Consumer Defensive ($15.88M or 9.86%).
The portfolio shows signs of both buying and selling activity, with the investor having positions in stocks that experienced large share increases (like KHC) and significant sales from holdings such as ORAMED.